HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mark F. Newman Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hill, S. E. Search for Related Content PubMed PubMed Citation Articles by Hill, S. E.

Ann Thorac Surg 2005;80:1401-1407
© 2005 The Society of Thoracic Surgeons

---

Original article: Cardiovascular

Cerebral Physiology of Cardiac Surgical Patients Treated with the Perfluorocarbon Emulsion, AF0144

^a Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina
^b Department of Anesthesiology, Mayo Clinic, Jacksonville, Florida
^c Neurologic Outcome Research Group (NORG) of the Duke Heart Center, Durham, North Carolina

Accepted for publication March 28, 2005.

^_* Address reprint requests to Dr Hill, Department of Anesthesiology, Box 3094, 3439 Hospital North, Duke University Medical Center, Durham, NC 27710 (Email: hill0012{at}mc.duke.edu).

BACKGROUND: Perfluorooctyl bromide is a biologically inert compound with short biologic retention and high oxygen solubility. The purpose of this study was to assess the effect of the perfluorocarbon emulsion, AF0144 (Perflubron, Alliance Pharmaceutical Corp, San Diego, CA), used in conjunction with acute normovolemic hemodilution on cerebral blood flow and cerebral emboli measurements during coronary artery bypass grafting with cardiopulmonary bypass.

METHODS: Thirty-six adult cardiac surgical patients were enrolled in a single-institution, randomized, controlled, single-blind dose escalation trial. Autologous whole blood was harvested from each patient to target an on-bypass hematocrit of 20% to 22%. Placebo, low dose (1.8 g/kg) or high dose (2.7 g/kg) AF0144 was administered. Transcranial Doppler ultrasonography was used to quantitate cerebral emboli and xenon-133 clearance was used to measure cerebral blood flow.

RESULTS: Cerebral blood flow was increased in both AF0144-treated groups compared with placebo (p = 0.006, low dose vs control; p = 0.036, high dose vs control). Numbers of cerebral emboli were greater in the high-dose AF0144-treated group versus control during the time periods from aortic cannulation through aortic cross-clamp placement (p = 0.026) and from aortic cross-clamp placement through cross-clamp removal (p = 0.008).

CONCLUSIONS: The perfluorocarbon emulsion, AF0144, increased cerebral blood flow during cardiopulmonary bypass. In addition, total cerebral emboli load during bypass was greater in patients receiving high-dose AF0144.

This article has been cited by other articles:

				F. de Lange, K. Yoshitani, A. D. Proia, G. B. Mackensen, and H. P. Grocott Perfluorocarbon Administration During Cardiopulmonary Bypass in Rats: An Inflammatory Link to Adverse Outcome? Anesth. Analg., January 1, 2008; 106(1): 24 - 31. [Abstract] [Full Text] [PDF]

				R. F. Mattrey Are Cerebral Emboli Real When Perfluorocarbon Emulsion (AF0144) is Used in Cardiac Surgery? Ann. Thorac. Surg., May 1, 2007; 83(5): 1922 - 1923. [Full Text] [PDF]

				S. E. Hill and H. P. Grocott Reply Ann. Thorac. Surg., May 1, 2007; 83(5): 1923 - 1923. [Full Text] [PDF]